Cancer Immunology, Immunotherapy

, Volume 57, Issue 10, pp 1511–1521 | Cite as

The E75 HER2/neu peptide vaccine

  • Elizabeth A. Mittendorf
  • Jarrod P. Holmes
  • Sathibalan Ponniah
  • George E. PeoplesEmail author
Symposium Paper


E75 (HER2/neu 369–377) is an immunogenic peptide from the HER2/neu protein which is overexpressed in many breast cancer patients. A large amount of preclinical work and a small number of Phase I trials have been completed evaluating the vaccine potential of the E75 peptide mixed with an immunoadjuvant. Our group has performed two concurrent E75 + GM-CSF Phase II trials in node-positive and node-negative disease-free breast cancer patients. These trials, totaling 186 patients, were designed to assess the ability of the E75 vaccine to prevent disease recurrence in these high risk patients. In this review article, we discuss the safety of the vaccine, the immunologic response to the peptide, and most importantly, the potential clinical benefit of the vaccine. The recurrence rate, mortality associated with recurrence, and the distribution of recurrences are presented and discussed. Additionally, the lessons learned from these trials to include optimal dosing and the need for booster inoculations are addressed. We also present data exploring possible explanations and mechanisms behind the potential clinical utility of this simple single epitope vaccine. Finally, we present some of the future directions for our Cancer Vaccine Development Program assessing multi-epitope peptide vaccines and combination immunotherapies.


Breast cancer E75 Peptide Vaccine Clinical trials 


  1. 1.
    Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268PubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175–182PubMedCrossRefGoogle Scholar
  3. 3.
    Van den Eynde B, Brichard VG (1995) New tumor antigens recognized by T cells. Curr Opin Immunol 7:674–681PubMedCrossRefGoogle Scholar
  4. 4.
    Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG (2003) Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9:3222–3234PubMedGoogle Scholar
  5. 5.
    Mittendorf EA, Peoples GE, Singletary SE (2007) Breast cancer vaccines: promise for the future or pipe dream? Cancer 110:1677–1686PubMedCrossRefGoogle Scholar
  6. 6.
    Mittendorf EA, Peoples GE (2007) HER-2/neu peptide breast cancer vaccines: current status and future directions. Breast Diseases: A Year Book Quarterly 17:318–320CrossRefGoogle Scholar
  7. 7.
    Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz K, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108PubMedGoogle Scholar
  8. 8.
    Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624–2632PubMedCrossRefGoogle Scholar
  9. 9.
    Disis ML, Grabstein KH, Sleath PR, Cheever MA (1999) Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5:1289–1297PubMedGoogle Scholar
  10. 10.
    Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117PubMedCrossRefGoogle Scholar
  11. 11.
    Knutson KL, Schiffman K, Cheever MA, Disis ML (2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014–1018PubMedGoogle Scholar
  12. 12.
    Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y (2002) Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8:3394–3400PubMedGoogle Scholar
  13. 13.
    Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG (2002) Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8:3407–3418PubMedGoogle Scholar
  14. 14.
    Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 92:432–436PubMedCrossRefGoogle Scholar
  15. 15.
    Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58:4902–4908PubMedGoogle Scholar
  16. 16.
    Bargmann CI, Hung MC, Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230PubMedCrossRefGoogle Scholar
  17. 17.
    Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Liebermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139PubMedCrossRefGoogle Scholar
  18. 18.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRefGoogle Scholar
  19. 19.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedCrossRefGoogle Scholar
  20. 20.
    Ioannides CG, Ioannides MG, O’Brian CA (1992) T-cell recognition of oncogene products: a new strategy for immunotherapy. Mol Carcinog 6:77–82PubMedCrossRefGoogle Scholar
  21. 21.
    Lee T (1990) Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. Springer-Verlag, New YorkGoogle Scholar
  22. 22.
    Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:4209–4220PubMedGoogle Scholar
  23. 23.
    Wölfel T, Klehmann E, Müller C, Schütt KH, Meyer zum Büschenfelde KH, Knuth A (1989) Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170:797–810PubMedCrossRefGoogle Scholar
  24. 24.
    Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM, Ioannides CG (2000) Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 6:4192–4200PubMedGoogle Scholar
  25. 25.
    Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA (1997) Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol 52:109–118PubMedCrossRefGoogle Scholar
  26. 26.
    Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S (2005) Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:7536–7545PubMedCrossRefGoogle Scholar
  27. 27.
    Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll M, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S (2008) Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute clinical trials group study I-01 and I-02. Clin Cancer Res 14:797–803PubMedCrossRefGoogle Scholar
  28. 28.
    Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE (2004) Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol 24:449–461PubMedCrossRefGoogle Scholar
  29. 29.
    Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175PubMedGoogle Scholar
  30. 30.
    Rammensee HG, Bachmann J, Stevanovic S (1997) MHC ligands and peptide motifs. Chapman & Hall, New YorkGoogle Scholar
  31. 31.
    Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (2002) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141–4149PubMedCrossRefGoogle Scholar
  32. 32.
    Amin E, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE (2008 Apr 8) Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother (Epub ahead of print)Google Scholar
  33. 33.
    Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Optimal dose and schedule of a HER2/neu (E75) peptide vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer, in pressGoogle Scholar
  34. 34.
    Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic patterns and their prognosis. South Med J 81:1109–1112PubMedGoogle Scholar
  35. 35.
    Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91:17–24PubMedCrossRefGoogle Scholar
  36. 36.
    Chen PW, Ananthaswamy HN (1993) Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 151:244–255PubMedGoogle Scholar
  37. 37.
    Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE (2007) Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 56:135–146PubMedCrossRefGoogle Scholar
  38. 38.
    Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE (2006) Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat 98:17–29PubMedCrossRefGoogle Scholar
  39. 39.
    Coutinho A, Hori S, Carvalho T, Carmalho I, Demengeot J (2001) Regulatory T cells: the physiology of autoreactivity in dominant tolerance and “quality control” of immune responses. Immunol Rev 182:89–98PubMedCrossRefGoogle Scholar
  40. 40.
    Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211–5218PubMedGoogle Scholar
  41. 41.
    Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE (2007) Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 17:687–694PubMedGoogle Scholar
  42. 42.
    Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP (2003) Progression of mouse mammary tumors: MCP-1-TNF-alpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 106:879–886PubMedCrossRefGoogle Scholar
  43. 43.
    Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M (2001) Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92:1085–1091PubMedCrossRefGoogle Scholar
  44. 44.
    Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34–40PubMedGoogle Scholar
  45. 45.
    Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE (2006) Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 12:478–486PubMedCrossRefGoogle Scholar
  46. 46.
    Sercarz EE (2000) Driver clones and determinant spreading. J Autoimmun 14:275–277PubMedCrossRefGoogle Scholar
  47. 47.
    Vanderlugt CJ, Miller SD (1996) Epitope spreading. Curr Opin Immunol 8:831–836PubMedCrossRefGoogle Scholar
  48. 48.
    Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE (2006) Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery 139:407–418PubMedCrossRefGoogle Scholar
  49. 49.
    Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE (2007) Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study. Ann Surg Oncol 14:3359–3368PubMedCrossRefGoogle Scholar
  50. 50.
    Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE (2006) Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106:2309–2317PubMedCrossRefGoogle Scholar
  51. 51.
    Khoo S, Storrer CE, Harris KA, Jama YH, Dehqanzada ZA, Murray JL, Shriver CD, von Hofe E, Ponniah S, Peoples GE (2006) Early results of a phase I clinical trial of an Ii-key/HER2/neu MHC class II peptide-base vaccine in breast cancer patients. J Clin Oncol 24:2532 (abstract)Google Scholar
  52. 52.
    Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE (2006) Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13:1085–1098PubMedCrossRefGoogle Scholar

Copyright information

© US Government 2008

Authors and Affiliations

  • Elizabeth A. Mittendorf
    • 1
  • Jarrod P. Holmes
    • 2
    • 3
  • Sathibalan Ponniah
    • 3
  • George E. Peoples
    • 3
    • 4
    Email author
  1. 1.Department of Surgical OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Division of Hematology and Medical Oncology, Department of MedicineNaval Medical Center San DiegoSan DiegoUSA
  3. 3.Cancer Vaccine Development Program, Department of SurgeryUnited States Military Cancer Institute, Uniformed Services University of the Health SciencesBethesdaUSA
  4. 4.Department of Surgery, General Surgery ServiceBrooke Army Medical CenterHoustonUSA

Personalised recommendations